Paul Bolno, Wave Life Sciences CEO

Wave Life Sci­ences touts Hunt­ing­ton's dis­ease win in Phase 1b/2a tri­al

Wave Life Sci­ences said Tues­day that its ex­per­i­men­tal Hunt­ing­ton’s dis­ease ther­a­py ef­fec­tive­ly low­ered the mu­tant hunt­ingtin pro­tein (mHTT) lev­els as­so­ci­at­ed with the dis­ease in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.